International Journal of Institutional Pharmacy and Life Sciences 2(2): March-April 2012

## INTERNATIONAL JOURNAL OF INSTITUTIONAL PHARMACY AND LIFE SCIENCES

**Pharmaceutical Sciences** 

Research Article.....!!!

Received: 06-04-2012; Accepted: 09-04-2012

# DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR THE SIMULTANEOUS ESTIMATION OF METOPROLOL SUCCINATE AND OLMESARTAN MEDOXOMIL IN TABLET DOSAGE FORM

Kevin H. Vachhani\*, Satish A. Patel, Himanshu H. Vachhani

Shree S. K. Patel College of Pharmaceutical Education & Research, Ganpat University, Kherva – 382711, Mehsana, Gujarat, India

#### **Keywords:**

Metoprolol Succinate, Olmesartan Medoxomil, RP-HPLC, Validation

### For Correspondence: Kevin H. Vachhani

Shree S. K. Patel College of Pharmaceutical Education & Research, Ganpat University, Kherva – 382711, Mehsana, Gujarat, India E-mail:

kevin\_8589@yahoo.in

#### **ABSTRACT**

A simple, selective and rapid reversed phase High Performance Liquid Chromatographic (RP-HPLC) method has been developed and validated for the simultaneous analysis of metoprolol succinate and olmesartan medoxomil in tablet dosage form. The separation was carried out using a mobile phase consisting of 20mM phosphate buffer and Acetonitrile with pH 3.0 adjusted with ortho phosphoric acid in the ratio of 60: 40 % v/v. The column used was Thermo C18, (150 mm x 4.6 mm i.d, 5µm) with flow rate of 1 ml / min using PDA detection at 223 nm. The described method was linear over a concentration range of 0.5-25 µg/ml and 0.5-25 µg/ml for the assay of metoprolol succinate and olmesartan medoxomil respectively. The retention times of metoprolol succinate and olmesartan medoxomil were found to be 2.28 and 5.35 min respectively. Results of analysis were validated statistically and by recovery studies. The mean recovery was  $99.60 \pm 1.46$  and  $99.69 \pm 1.31$  for metoprolol succinate and olmesartan medoxomil, respectively. The limit of detection (LOD) and the limit of quantification (LOQ) for Metoprolol Succinate and Olmesartan Medoxomil were found to be 0.137 and 0.416 µg/ml and 0.144 and 0.437 µg/ml respectively. The results of the study showed that the proposed RP-HPLC method is simple, rapid, precise and accurate, which is useful for the routine determination of metoprolol succinate and olmesartan medoxomil in its pharmaceutical dosage form.

#### INTRODUCTION

Metoprolol succinate (METO) is chemically (RS)-1-(Isopropylamino)-3-[4-(2methoxyethyl)phenoxylpropan-2-ol succinate [1], is a cardio selective β-blocker, used in the treatment of hypertension, angina pectoris, arrhythmia, myocardial infraction and heart failure<sup>[2]</sup>. It is official in  $IP^{[3]}$ ,  $BP^{[4]}$  and  $USP^{[5]}$ .  $IP^{[3]}$ ,  $BP^{[4]}$  and  $USP^{[5]}$ describes potentiometry method for its estimation. Literature survey reveals UV spectrophotometric method<sup>[6]</sup>, RP-HPLC method<sup>[7]</sup>. validated HPLC method for estimation of metoprolol in human plasma<sup>[8]</sup>, simultaneous spectrophotometric method with other drug<sup>[9]</sup> and RP-HPLC method with other drug<sup>[10]</sup> in pharmaceutical dosage forms as well as in biological fluids. Olmesartan medoxomil (OLME) is chemically (5-methyl-2-oxo-2*H*-1,3-dioxol-4-yl)methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1- $(\{4-[2-(2H-1,2,3,4-tetrazol-5-vl)phenyl\}phenyl\}methyl)-1H-imidazole-5-carboxylate<sup>[11]</sup>, is a$ angiotensin II receptor antagonist for the treatment of hypertension<sup>[12]</sup>. Olmesartan medoxomil is not official in any pharmacopoeia. Literature survey reveals stress induced method UV spectrometric method<sup>[13]</sup>, HPTLC<sup>[14]</sup>, simultaneous estimation with other drug<sup>[15]</sup>, HPTLC with other drug<sup>[16]</sup>, RP-HPLC with other drug<sup>[17]</sup>, stability-indicating LC method<sup>[18]</sup> for the determination of OLME. The combined dosage forms of METO and OLME are available in the market for the treatment of hypertension. The present manuscript describes simple, sensitive, accurate, precise, rapid and economic chromatographic method (RP-HPLC) for simultaneous estimation of metoprolol succinate and olmesartan medoxomil in tablet dosage form.

Fig. 1: Structural formula of metoprolol succinate

Fig. 2: Structural formula of olmesartan medoxomil

#### MATERIALS AND METHODS

#### Apparatus

RP-HPLC instrument (Shimadzu, LC-2010 $C_{\rm HT}$ , Japan) equipped with a UV-Visible detector and a photodiode array detector, auto sampler, Thermo  $C_{18}$  column (150 mm  $\times$  4.6 mm i.d., 5  $\mu$ m particle size) was used. Chromatograms were automatically obtained by LC-solution system software. A Sartorius CP224S analytical balance (Gottingen, Germany), an ultrasonic bath (Frontline FS 4, Mumbai, India) was used in the study.

#### **Reagents and Materials**

METO and OLME bulk powder was kindly gifted by Astron Research Centre, Ahmedabad, Gujarat, India. The commercial fixed dose combination product was procured from the local market. Methanol AR Grade was procured from Finar Chemicals Ltd., Ahmedabad, India.

#### Preparation of standard stock solutions

An accurately weighed quantity of METO (10 mg) and OLME (10 mg) were transferred to a separate 100 ml volumetric flask and dissolved and diluted to the mark with methanol to obtain standard solution having concentration of METO (100  $\mu$ g/ml) and OLME (100  $\mu$ g/ml).

#### **Preparation of Working Standard Solutions**

An aliquot of stock solution 25 ml was transferred in 50 ml volumetric flask and adjusted up to mark with methanol having concentration (50 µg/ml)

#### **Preparation of Sample Solution**

Twenty tablets were weighed and powdered. The powder equivalent to 25 mg METO and 20 mg OLME was transferred to 100 ml volumetric flask. Methanol (50 ml) was added to it and sonicated for 20 min. The volume was adjusted up to the mark with methanol after filtration of sonicated solution.

#### Preparation of pH 3.0 Buffer Solution

Potassiumdihydrogen phosphate (20 mM, 2.72 gm) in 1000ml of millequivalent water was solubilised and adjusted the pH to  $3.0 \pm 0.05$  with ortho phosphoric acid solution.

#### **Determination of Analytical Wavelength**

The standard solution of METO and OLME were injected under the chromatographic condition described above. Detection was carried out at different wavelength best response was achieved at 223 nm with PDA detector. So both drugs were detected at this analytical wavelength (Fig. 3).




Fig. 3: Overlain zero-order absorption spectra of METO and OLME in methanol Methodology

To optimize the RP-HPLC parameters, several mobile phase compositions were tried. A satisfactory separation and good peak symmetry for METO and OLME was obtained with a mobile phase Phosphate Buffer 20 mM (pH 3.0): Acetonitrile [60:40 v/v] at a flow rate of 1.0 ml/min to get better reproducibility and repeatability. Quantification was carried out at 223 nm based on peak area. Complete resolution of the peaks with clear baseline was obtained (Fig. 4). System suitability test parameters for METO and OLME for the proposed method are reported in Table 1.




Fig.: 4 Chromatogram of Standard Solution of METO and OLME at 223 nm

TABLE 1: System Suitability Parameters of Chromatogram for METO and OLME

Parameters	METO ± RSD	OLME ± RSD
	$(\mathbf{n}=6)$	$(\mathbf{n} = 6)$
Retention time (min)	$2.28 \pm 0.11$	$5.35 \pm 0.06$
Tailing factor	$1.23 \pm 1.44$	$0.84 \pm 0.99$
Theoretical plates	$2125 \pm 0.78$	$4948 \pm 0.51$
Resolution	$11.457 \pm 0.56$	

#### Validation of the proposed method

The proposed method was validated according to the International Conference on Harmonization (ICH) guidelines<sup>[19]</sup>.

#### Linearity

Linear correlation was obtained between peak area Vs concentrations of METO and OLME in the concentration ranges of 0.5-25  $\mu$ g/ml. Regression parameters are mentioned in table 4 and the calibration curves of these two drugs at 223 nm are shown in Fig. 5 & Fig.6.




Fig: 5 Calibration Curve of METO at 223 nm




Fig: 6 Calibration Curve of OLME at 223 nm

#### **Method Precision (% Repeatability)**

The RSD values for METO and OLME were found to be 0.64 and 0.63 %, respectively. The RSD values were found to be <2 %, which indicates that the proposed method is repeatable.

#### **Intermediate Precision (Reproducibility)**

The low RSD values of interday (0.36-1.08 % and 0.42-1.33 %) and intraday (0.56 - 1.57 % and 0.51 - 1.41 %) for METO and OLME, respectively, reveal that the proposed method is precise.

#### Limit of detection and Limit of quantification

Limit of detection (LOD) values for METO and OLME were found to be 0.137  $\mu$ g/ml and 0.144  $\mu$ g/ml, respectively and Limit of quantification (LOQ) values for METO and OLME were found to be 0.416  $\mu$ g/ml and 0.437  $\mu$ g/ml, respectively (Table 4). These data show that the proposed method is sensitive for the determination of METO and OLME.

#### Accuracy

The recovery experiment was performed by the standard addition method. The recoveries obtained were  $100.1 \pm 1.47$  % and  $99.79 \pm 1.28$  % for METO and OLME, respectively (Table 2). The low value of standard deviation indicates that the proposed method is accurate. Results of recovery studies are shown in Table 2.

TABLE 2: Recovery Data for the proposed Method

Drug	Level	Amount of	Amount of	Mean
		sample taken	standard	% Recovery ±
		(µg/ml)	spiked (%)	$\mathbf{SD}^*$
	I	10	50 %	99.24 ± 1.41
METO	II	10	100 %	$99.05 \pm 1.92$
	III	10	150 %	$100.51 \pm 1.05$
	I	8	50 %	$99.25 \pm 1.13$
OLME	II	8	100 %	$100.82 \pm 1.04$
	III	8	150 %	$98.99 \pm 1.77$

\* Mean % Recovery  $\pm$  SD of six observations, SD = standard deviation

#### **Assay of the Pharmaceutical Formulation**

The proposed validated method was successfully applied to determine METO and OLME in their tablet dosage form. The result obtained for METO and OLME was comparable with the corresponding labeled amounts (Table 3). The RP-HPLC chromatogram for METO and OLME in sample was recorded and is shown in Fig. 7.




Fig: 7 Chromatogram of sample solution of METO and OLME at 223 nm

**TABLE 3:** Analysis of Formulation of Metoprolol and Olmesartan by Proposed Method (n = 6)

	•					`
Tablet	Label claim (mg)		Amount found (mg)		% Label claim $\pm$ SD (n=6)*	
	METO	OLME	METO	OLME	METO	OLME
I	25	20	24.87	19.87	$99.48 \pm 0.777$	$99.35 \pm 1.488$
II	25	20	24.95	20.02	$99.83 \pm 0.687$	$100.10 \pm 0.140$

\*SD = standard deviation and n is number of determinations

#### RESULTS AND DISCUSSION

A RP-HPLC method was developed and validated for the determination of METO and OLME in tablet dosage forms on a column (C18, 150 X 4.6 i.d.,  $5\mu$ m) with variable wavelength detection at 223 nm. The retention times of METO and OLME was 2.28 min and 5.35 min, respectively.

Linear correlation was obtained between area and concentrations of METO and OLME in the concentration ranges of 0.5-25  $\mu$ g/ml and 0.5-25  $\mu$ g/ml, respectively. The linearity of the calibration curve was validated by the high values of correlation coefficient of regression (Table 4). The RSD values of were found to be 0.39 % and 0.42 of METO and OLME, respectively. Relative standard deviation was less than 2 %, which indicates that proposed method is repeatable. The low RSD values of interday (0.36-1.08 % for METO and 0.42-1.33 % for OLME) and intraday (0.56 – 1.57 % for METO and 0.51 – 1.41% for OLME) at 223 nm, reveal that the proposed method is precise (Table 4). The limit of detection (LOD) and the limit of quantification (LOQ) for METO and OLME were found to be 0.137 and 0.416  $\mu$ g/ml and 0.144 and 0.437  $\mu$ g/ml, respectively. These data show that method is sensitive for the determination of METO and OLME.

The recovery experiment was performed by the standard addition method. The mean recoveries were  $99.60\pm1.46$  and  $99.69\pm1.31$  for METO and OLME, respectively (Table 4). The results of recovery studies indicate that the proposed method is highly accurate. The proposed validated

method was successfully applied to determine METO and OLME in their tablet dosage form. The results obtained for METO and OLME were comparable with the corresponding labeled amounts (Table 3). No interference of the excipients with the absorbance of interest appeared; hence the proposed method is applicable for the routine simultaneous estimation of METO and OLME in pharmaceutical dosage forms.

TABLE 4: Regression Analysis Data and Summary of Validation Parameter for the proposed Method

Parameters	RP-HPLC method			
	METO	OLME		
Concentration range (µg/ml)	0.5-25	0.5-25		
Slope	41687	67291		
Intercept	17188	30308		
Correlation coefficient	0.9991	0.9993		
LOD <sup>a</sup> (µg/ml)	0.1376	0.1443		
LOQ <sup>b</sup> (µg/ml)	0.4162	0.4373		
% Recovery (Accuracy, n = 6)	99.60± 1.46	$99.69 \pm 1.31$		
Repetability (% RSD, n = 6)	0.39	0.42		
Precision (%RSD) <sup>c</sup>				
Interday $(n = 3)$	0.36-1.08	0.42-1.33		
Intraday $(n = 3)$	0.56 – 1.57	0.51 – 1.41		

<sup>&</sup>lt;sup>a</sup>LOD = Limit of detection. <sup>b</sup>LOQ = Limit of quantification. <sup>c</sup>RSD = Relative standard deviation.

#### CONCLUSION

In this proposed method the linearity is observed in the concentration range of 1-10 $\mu$ g/ml with co-efficient of correlation, (r<sup>2</sup>) = 0.9991 and (r<sup>2</sup>) = 0.9993 for METO and OLME, respectively at 223 nm. The result of the analysis of pharmaceutical formulation by the proposed method is highly reproducible and reliable and it is in good agreement with the label claim of the drug. The method can be used for the routine analysis of the METO and OLME in combined dosage form without any interference of excipients.

#### ACKNOWLEDGEMENT

The authors are thankful to Astron research centre, Ahmedabad, Gujarat, India for providing gift sample of METO and OLME for research. The authors are highly thankful to Shree S. K. Patel College of Pharmaceutical Education & Research, Ganpat University, Kherva, Mehsana, Gujarat, India for providing all the facilities to carry out the work.

#### REFERENCES

- 1. Maryadele, J. O'Neil., Eds., In; The Merck Index. An Encyclopedia of Chemicals, Drugs and Biologicals, 14th Edn., Merck & Co., Inc., Whitehouse Station. NJ, 2006, 6151: 1060.
- 2. Sweetman, S.C., Martindale: The Complete Drug Reference, 35th ed, London, UK, Pharmaceutical Press, 2007; 1201.
- 3. Indian Pharmacopeia, Vol. II. New Delhi, Controller Publication, Govt of India. 2010; 1681.
- 4. British Pharmacopoeia, Vol II. London, British Pharmacopoeia Commission; 2010; 1419.
- 5. The United State Pharmacopeia. USP28-NF23. Rockville MD: United State Pharmacopeial Convention, Inc; 2005; 1279.
- 6. Sawant S.D., Ghante M.R., Deshpande A.S., Shah B. Three Simple Spectrometric Methods for Metoprolol Succinate in Tablet Dosage Form. International Journal of Chemical and Analytical Science 2010; 1(9): 217-218.
- 7. Vuzic Z., Radulovic D., Zivanovic D. Spectrophotometric Investigation of Metoprolol-Benzyl Orange and its Application to the Assay in Pharmaceutical Dosage Forms. Elsevier, Lausanne, SUISSE 1995; 50(4): 281-284.
- 8. Aqil M., Ali A., Ahad A., Sultana Y., Najmi A.K., Saha N. A Validated HPLC Method for Estimation of Metoprolol in Human Plasma. ACTA Chromatographica 2007; 19: 130-140.
- 9. Sureshkumar K., Ravikumar R., Rajasekaran A., Ravichandran V. Simultaneous Spectrophotometric Determination of Metoprolol Tartrate and Ramipril. Digest Journal of Nanomaterials and Biostructures 2010 March; 5(1): 173-176.
- 10. Rao M.M.P., Rahaman S.A., Prasad Y.R., Reddy P.G. RP-HPLC Method of Simultaneous Estimation of Amlodipine Besylate and Metoprolol in Combined Dosage Form. International Journal of Pharmaceutical Research and Development 2010 Nov; 2(9): 69-76.
- 11. Maryadele, J. O'Neil., Eds., In; The Merck Index. An Encyclopedia of Chemicals, Drugs and Biologicals, 14th Edn., Merck & Co., Inc., Whitehouse Station. NJ, 2006, 6839: 1178.
- 12. Sweetman, S.C., Martindale: The Complete Drug Reference, 35th ed, London, UK, Pharmaceutical Press, 2007: 1224.
- 13. Dash A.K., Stress Induced Method Development and Validation of Olmesartan in Bulk Dosage Form by UV Spectrometric Method. Pharmaceutical and Biotechnology.
- 14. Parambi D.T., Dr. Mathew M., Dr. Ganesan V., Jose A., Dr. Revikumar K.G. A Validated HPTLC Determination of Angiotensin Receptor Blocker Olmesartan Medoxomil from Tablet Dosage Form. International Journal of Pharmaceutical Sciences Review And Research 2010 September – October; 4(3): 36-39.

- 15. Wankhede S.B., Wadkar S.B., Raka K.C. and Chitlange S.S. Simultaneous Estimation of Amlodipine Besilate and Olmesartan Medoxomil in Pharmaceutical Dosage Form. Indian Journal of Pharmaceutical Science 2009 Sep-Oct; 71(5): 563–567.
- 16. Shah N.J., Suhagia B.N., Development and Validation of A Simultaneous HPTLC Method for The Estimation of Olmesartan Medoxomil and Hydrochlorothiazide in Tablet Dosage Form. Indian Journal of Pharmaceutical Science 2007; 69(6): 834-836.
- 17. Patil P.S., More H.N., Pishwikar S.A. RP-HPLC Method for Simultaneous Estimation of Amlodipine Besylate and Olmesartan Medoxomil from Tablet. International Journal of Pharmacy and Pharmaceutical Sciences 2011; 3(suppl 3): 146-149.
- 18. Rane V.P., Patil K.R., Sangshetti J.N., Yeole R.D., Shinde D.B. Stability-indicating LC Method for the Determination of Olmesartan in Bulk Drug and in Pharmaceutical Dosage Form. Chromatographiya 2009; 69(1-2): 169-173.
- 19. The International Conference on Harmonization, Q2 (R1), Validation of Analytical Procedure: Text and Methodology, 2005.